| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| CPI-RSV-F Vaccine | BLB-201 | Phase 2 Clinical | Blue Lake Biotechnology Inc | Respiratory Syncytial Virus Infections | 詳細 |
| RSV vaccine (Vaxart) | Phase 1 Clinical | Vaxart Biosciences Inc | Respiratory Syncytial Virus Infections | 詳細 | |
| GR-2102 | GR2102; GR-2102 | Phase 1 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Respiratory Syncytial Virus Infections | 詳細 |
| Palivizumab biosimilar (mAbxience) | MB-05 | Phase 1 Clinical | Mabxience Sa | 詳細 | |
| RSM-01 | Phase 1 Clinical | Bill & Melinda Gates Medical Research Institute | Respiratory Syncytial Virus Infections | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Nirsevimab | Anti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTE | Approved | Aimm Therapeutics, MedImmune Inc, Sanofi | Beyfortus, 乐唯初 | EU | Respiratory Syncytial Virus Infections | Sanofi Winthrop Industrie SA | 2022-10-31 | Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections | 詳細 |
| Palivizumab | ABT-315; MEDI-493 | Approved | Abbvie Inc, Medimmune Llc | Synagis | United States | Respiratory Syncytial Virus Infections | Swedish Orphan Biovitrum Ab (Publ) | 1998-06-19 | Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections | 詳細 |
| Respiratory syncytial virus immune globulin | RSV-IGIV | Approved | Medimmune | RespiGam | United States | Respiratory Syncytial Virus Infections | null | 1996-01-01 | Respiratory Syncytial Virus Infections | 詳細 |